Disease modeling with in vitro cellular systems enables researchers to recreate and study the mechanisms underlying neurological disorders in controlled experimental settings. In neuroscience and stem cell biology, this typically involves patient-derived or genetically modified neuronal models to capture key features of disease at molecular, cellular, and network levels. These models can reveal pathological changes in excitability, synaptic transmission, and network dynamics, which are often linked to specific genetic mutations or environmental insults. By reproducing disease-relevant functional and structural abnormalities, in vitro systems provide a powerful platform for dissecting disease mechanisms, identifying biomarkers, and testing candidate therapeutics. When combined with electrophysiology, imaging, and multi-omics approaches, disease modeling offers deep insight into how dysfunction emerges and progresses in the nervous system.
MaxWell Biosystems’ HD-MEA platforms bring powerful capabilities to in vitro disease modeling by enabling detailed, label-free recordings of pathological activity across single cells and networks. With unmatched signal fidelity and resolution, researchers can detect subtle dysfunctions, quantify altered phenotypes, and track disease progression or rescue effects over time. This enables researchers to link cellular dysfunction to disease mechanisms and establish in vitro assays for testing therapeutic strategies in a human-relevant context.
fig%202.avif)
.png){kind=spacer}
